Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Dynamic Changes in Arteriovenous Malformations (AVMs): Spontaneous Growth and Resolution of AVM-Associated Aneurysms in Two Pediatric Patients.

Koch MJ, Mahal BAV, Hadzipasic M, Fehnel KP, Chapman PH, Loeffler JS, Orbach DB, Smith ER.

Pediatr Neurosurg. 2019 Oct 9:1-5. doi: 10.1159/000501041. [Epub ahead of print]

PMID:
31597140
2.

United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015.

Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA.

Prostate Cancer Prostatic Dis. 2019 Oct 7. doi: 10.1038/s41391-019-0175-9. [Epub ahead of print]

PMID:
31591454
3.

Radiation Therapy Pain Management: Prevalence of Symptoms and Effectiveness of Treatment Options.

Lamba N, Mahal BA, Martinez R, Leland P, Shih HA.

Clin J Oncol Nurs. 2019 Oct 1;23(5):514-521. doi: 10.1188/19.CJON.514-521.

PMID:
31538974
4.

Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+ OPC.

Sanford NN, Hwang WL, Pike LRG, Lam AC, Royce TJ, Mahal BA.

Oral Oncol. 2019 Sep 16;98:28-34. doi: 10.1016/j.oraloncology.2019.09.009. [Epub ahead of print]

PMID:
31536843
5.

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.

Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM.

Clin Cancer Res. 2019 Sep 12. doi: 10.1158/1078-0432.CCR-19-1587. [Epub ahead of print]

PMID:
31515456
6.

Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers.

Cole AP, Lu C, Krimphove MJ, Szymaniak J, Sun M, Fletcher SA, Lipsitz SR, Mahal BA, Nguyen PL, Choueiri TK, Kibel AS, Haider AH, Trinh QD.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1049-1058. doi: 10.6004/jnccn.2019.7296.

PMID:
31487683
7.

Prevalence of chronic pain among cancer survivors in the United States, 2010-2017.

Sanford NN, Sher DJ, Butler SS, Xu X, Ahn C, Aizer AA, Mahal BA.

Cancer. 2019 Aug 22. doi: 10.1002/cncr.32450. [Epub ahead of print]

PMID:
31436323
8.

Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level.

Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):941-948. doi: 10.6004/jnccn.2018.7283.

PMID:
31390585
9.

Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States.

Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, Tishler RB, Margalit DN.

Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1660-1667. doi: 10.1158/1055-9965.EPI-19-0038. Epub 2019 Jul 29.

PMID:
31358520
10.

The Use of e-Cigarettes in Patients With Cancer-A Double Shipwreck-In Reply.

Sanford NN, Mahal BA.

JAMA Oncol. 2019 Jul 25. doi: 10.1001/jamaoncol.2019.2396. [Epub ahead of print] No abstract available.

PMID:
31343667
11.

Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer.

Alimena S, Yang DD, Melamed A, Mahal BA, Worley MJ Jr, Feldman S, Elias KM, Orio PF, Lee LJ, King M.

Gynecol Oncol. 2019 Sep;154(3):595-601. doi: 10.1016/j.ygyno.2019.06.022. Epub 2019 Jul 7.

PMID:
31292103
12.

Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer.

Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):621-627. doi: 10.1016/j.ijrobp.2019.06.2510. Epub 2019 Jul 2.

PMID:
31271825
13.

Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.

Mahal AR, Butler S, Franco I, Muralidhar V, Larios D, Pike LRG, Zhao SG, Sanford NN, Dess RT, Feng FY, D'Amico AV, Spratt DE, Yu JB, Nguyen PL, Rebbeck TR, Mahal BA.

Cancer. 2019 Oct 1;125(19):3338-3346. doi: 10.1002/cncr.32332. Epub 2019 Jun 28.

PMID:
31251398
14.

Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis.

Bitterman DS, Sanford NN, Niemierko A, Mahal BA, Qadan M, Ganguli S, Blaszkowsky LS, Zhu AX, Hong TS, Devlin PM, Goyal L, Wo JY.

Am J Clin Oncol. 2019 Jul;42(7):564-572. doi: 10.1097/COC.0000000000000560.

PMID:
31166209
15.

Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.

Alshalalfa M, Nguyen PL, Beltran H, Chen WS, Davicioni E, Zhao SG, Rebbeck TR, Schaeffer EM, Lotan TL, Feng FY, Mahal BA.

Eur Urol Oncol. 2019 Jul;2(4):405-412. doi: 10.1016/j.euo.2019.05.001. Epub 2019 Jun 2.

PMID:
31164324
16.

Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.

Butler SS, Mahal BA, Lamba N, Mossanen M, Martin NE, Mouw KW, Nguyen PL, Muralidhar V.

Cancer. 2019 Sep 15;125(18):3164-3171. doi: 10.1002/cncr.32202. Epub 2019 May 31.

PMID:
31150125
17.

Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy of Gleason 9-10 Prostate Cancer.

Muralidhar V, Mahal BA, Butler S, Lamba N, Yang DD, Leeman J, D'Amico AV, Nguyen PL, Trinh QD, Orio PF 3rd, King MT.

J Urol. 2019 May 30:101097JU0000000000000352. doi: 10.1097/JU.0000000000000352. [Epub ahead of print]

PMID:
31144590
18.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE.

JAMA Oncol. 2019 Jul 1;5(7):975-983. doi: 10.1001/jamaoncol.2019.0826.

19.

Active Surveillance for Low-Risk Prostate Cancer in Black Patients.

Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA.

N Engl J Med. 2019 May 23;380(21):2070-2072. doi: 10.1056/NEJMc1900333. No abstract available.

PMID:
31116925
20.

Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015.

Sanford NN, Sher DJ, Butler S, Xu X, Ahn C, D'Amico AV, Rebbeck T, Aizer AA, Mahal BA.

JAMA Netw Open. 2019 May 3;2(5):e193759. doi: 10.1001/jamanetworkopen.2019.3759.

21.

Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017.

Sanford NN, Lam MB, Butler SS, Ahn C, Beg MS, Aizer AA, Mahal BA.

JAMA Oncol. 2019 May 15:e191973. doi: 10.1001/jamaoncol.2019.1973. [Epub ahead of print]

PMID:
31091534
22.

Racial Disparities in Low-Risk Prostate Cancer-Reply.

Mahal BA, Huang FW.

JAMA. 2019 May 7;321(17):1727-1728. doi: 10.1001/jama.2019.2088. No abstract available.

PMID:
31063570
23.

Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.

Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY.

Clin Cancer Res. 2019 Jul 15;25(14):4290-4299. doi: 10.1158/1078-0432.CCR-19-0404. Epub 2019 Apr 22.

PMID:
31010837
24.

Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States.

Sanford NN, Sher DJ, Ahn C, Aizer AA, Mahal BA.

JAMA Oncol. 2019 May 1;5(5):735-737. doi: 10.1001/jamaoncol.2019.0349. No abstract available.

PMID:
30973579
25.

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.

Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789. doi: 10.1016/j.ijrobp.2019.03.051. Epub 2019 Apr 6.

PMID:
30959121
26.

Trends in Smoking and e-Cigarette Use Among US Patients With Cancer, 2014-2017.

Sanford NN, Sher DJ, Xu X, Aizer AA, Mahal BA.

JAMA Oncol. 2019 Mar 1;5(3):426-428. doi: 10.1001/jamaoncol.2018.6858. No abstract available.

PMID:
30763430
27.

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015.

Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D'Amico AV, Nguyen PL.

JAMA. 2019 Feb 19;321(7):704-706. doi: 10.1001/jama.2018.19941. No abstract available.

28.

Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores.

Mahal BA, Alshalalfa M, Spratt DE, Davicioni E, Zhao SG, Feng FY, Rebbeck TR, Nguyen PL, Huang FW.

Eur Urol. 2019 Jun;75(6):1038-1040. doi: 10.1016/j.eururo.2019.01.010. Epub 2019 Jan 22. No abstract available.

PMID:
30683576
29.

Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?

Cole AP, Fletcher SA, Berg S, Nabi J, Mahal BA, Sonpavde GP, Nguyen PL, Lipsitz SR, Sun M, Choueiri TK, Preston MA, Kibel AS, Trinh QD.

Cancer. 2019 Apr 15;125(8):1319-1329. doi: 10.1002/cncr.31926. Epub 2019 Jan 11.

PMID:
30633323
30.

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.

Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY.

Clin Cancer Res. 2019 Apr 15;25(8):2450-2457. doi: 10.1158/1078-0432.CCR-18-3121. Epub 2018 Dec 20.

PMID:
30573691
31.

Prostate Cancer-Specific Mortality Across Gleason Scores in Black vs Nonblack Men.

Mahal BA, Berman RA, Taplin ME, Huang FW.

JAMA. 2018 Dec 18;320(23):2479-2481. doi: 10.1001/jama.2018.11716. No abstract available.

PMID:
30561471
32.

Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL.

Eur Urol. 2019 Jan;75(1):35-41. doi: 10.1016/j.eururo.2018.08.033. Epub 2018 Oct 24.

PMID:
30554605
33.

Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals.

Krimphove MJ, Fletcher SA, Cole AP, Berg S, Sun M, Lipsitz SR, Mahal BA, Nguyen PL, Choueiri TK, Kibel AS, Kluth LA, Weissman JS, Trinh QD.

J Urol. 2019 Apr;201(4):735-741. doi: 10.1016/j.juro.2018.10.024.

PMID:
30414956
34.

HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx.

Pike LRG, Hwang WL, Royce TJ, Sanford NN, Mahal BA.

Oral Oncol. 2018 Nov;86:69-74. doi: 10.1016/j.oraloncology.2018.09.007. Epub 2018 Sep 15.

PMID:
30409322
35.

Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers.

Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang L.

Cancer Cell. 2018 Oct 8;34(4):549-560.e9. doi: 10.1016/j.ccell.2018.08.019.

36.

The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors.

Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, Cagney DN, Aizer AA, Alexander BM, Rahma O, Balboni T, Ott PA, Hodi FS, Schoenfeld JD.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):142-151. doi: 10.1016/j.ijrobp.2018.09.010. Epub 2018 Sep 15.

PMID:
30227198
37.

Sex Disparity and Copy Number Alterations in Esophageal Squamous Cell Carcinoma.

Sanford NN, Mahal BA, Royce TJ, Pike LRG, Hwang WL.

Clin Gastroenterol Hepatol. 2019 May;17(6):1207-1209. doi: 10.1016/j.cgh.2018.08.026. Epub 2018 Aug 16.

PMID:
30120994
38.
39.

Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality.

Mahal BA, Chen MH, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.

J Natl Compr Canc Netw. 2018 Jun;16(6):727-734. doi: 10.6004/jnccn.2018.7010.

PMID:
29891524
40.

Safety of combining radiotherapy with immune-checkpoint inhibition.

Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS.

Nat Rev Clin Oncol. 2018 Aug;15(8):477-494. doi: 10.1038/s41571-018-0046-7. Review.

PMID:
29872177
41.

Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce.

Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

Am J Med. 2018 May;131(5):517-523. doi: 10.1016/j.amjmed.2017.11.039. Epub 2018 Mar 16.

PMID:
29555248
42.

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF 3rd, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL.

Eur Urol. 2018 Aug;74(2):146-154. doi: 10.1016/j.eururo.2018.01.043. Epub 2018 Feb 22.

43.

Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials.

Vastola ME, Yang DD, Muralidhar V, Mahal BA, Lathan CS, McGregor BA, Nguyen PL.

JAMA Oncol. 2018 Mar 1;4(3):413-414. doi: 10.1001/jamaoncol.2017.4658. No abstract available.

44.

Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.

Yang DD, Muralidhar V, Mahal BA, Nguyen PL, Devlin PM, King MT, Orio PF 3rd.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):53-58. doi: 10.1016/j.ijrobp.2017.08.046. Epub 2017 Sep 9.

PMID:
29254781
45.

Travel distance and stereotactic body radiotherapy for localized prostate cancer.

Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF 3rd, Nguyen PL.

Cancer. 2018 Mar 15;124(6):1141-1149. doi: 10.1002/cncr.31190. Epub 2017 Dec 12.

46.

Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.

Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF 3rd, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL.

Clin Genitourin Cancer. 2018 Jun;16(3):226-234. doi: 10.1016/j.clgc.2017.10.013. Epub 2017 Nov 9.

PMID:
29196209
47.

Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance.

Mahal AR, Mahal BA, Nguyen PL, Yu JB.

Cancer. 2018 Feb 15;124(4):752-759. doi: 10.1002/cncr.31106. Epub 2017 Oct 30.

48.

Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy.

Yang DD, Muralidhar V, Mahal BA, Beard CJ, Mouw KW, Martin NE, Orio PF 3rd, King MT, Nguyen PL.

Am J Clin Oncol. 2018 Oct;41(10):953-959. doi: 10.1097/COC.0000000000000410.

PMID:
29045266
49.

Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.

Yang DD, Mahal BA, Muralidhar V, Boldbaatar N, Labe SA, Nezolosky MD, Vastola ME, Beard CJ, Martin NE, Mouw KW, Orio PF 3rd, King MT, Nguyen PL.

Cancer. 2017 Dec 15;123(24):4832-4840. doi: 10.1002/cncr.30948. Epub 2017 Aug 22.

50.

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL.

Eur Urol Focus. 2019 Jan;5(1):69-76. doi: 10.1016/j.euf.2017.05.011. Epub 2017 Jun 17.

PMID:
28753811

Supplemental Content

Loading ...
Support Center